SCHEMBL3681389

SCHEMBL3681389

CCOC(=O)CCc1cnc(OCc2ccc(C(F)(F)F)cc2)c(-c2ccc3ccccc3c2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.48
SYK P43405 3/20 0.42
CCNC P24863 2/20 0.41
CDK8 P49336 2/20 0.41
PPARG P37231 3/20 0.41
PPARD Q03181 3/20 0.41
PPARA Q07869 3/20 0.41
FFAR1 O14842 1/20 0.40
FFAR4 Q5NUL3 1/20 0.40
EPHX2 P34913 1/20 0.39
DHFR P00374 1/20 0.38
PSEN1 P49768 3/20 0.38
PSEN2 P49810 1/20 0.38
APH1B Q8WW43 1/20 0.38
NCSTN Q92542 1/20 0.38
APH1A Q96BI3 1/20 0.38
PSENEN Q9NZ42 1/20 0.38
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38
RXRG P48443 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3684473 0.88 FFAR1 (0.52) CCNCCDK8PPARGPPARDPPARA
SCHEMBL5751152 0.82 CCNC (0.45) MAOBSYKCCNCCDK8PPARG
SCHEMBL3692367 0.80 MAOB (0.46) MAOBSYKPPARGFFAR1FFAR4
SCHEMBL3682341 0.79 CCNC (0.47) SYKCCNCCDK8
SCHEMBL3685341 0.79 CCNC (0.43) SYKCCNCCDK8
SCHEMBL3682333 0.78 CCNC (0.42) SYKCCNCCDK8EPHX2
SCHEMBL28764339 0.78 CCNC (0.43) SYKCCNCCDK8PPARGPPARD
SCHEMBL3681908 0.78 CCNC (0.43) SYKCCNCCDK8PPARGPPARD
SCHEMBL16539838 0.76 CYP4F2 (0.44) SYKFFAR1FFAR4EPHX2PSEN1
SCHEMBL3881631 0.75 CCNC (0.45) MAOBCCNCCDK8FFAR1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100048893-A1 Substituted arylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-02-25 US disclosed
US-20090062530-A1 Substituted arylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2009-03-05 US disclosed
US-7470807-B2 Suppress production of both prostaglandins and leukotrienes and have reduced side effects; treatment of various inflammatory diseases, autoimmune diseases, allergic diseases, pain and fibrosis; for example, methyl 3-[3-acetylamino-4-cyclopentyloxy-5-(naphthalen-2-yl)phenyl]propionate ASAHI KASEI PHARMA CORPORATION (JP) 2008-12-30 US disclosed
US-20070213333-A1 Substituted arylalkanoic acid derivatives and use thereof ASAHI KASEI PHAMA CORPORATION (JP) 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048893-A1 Substituted arylalkanoic acid derivatives and use thereof CYSLTR1, CYSLTR2, LTB4R2 MAOB 886/4885SYK 2394/4885CCNC 3082/4885
US-20070213333-A1 Substituted arylalkanoic acid derivatives and use thereof CYSLTR1, CYSLTR2, LTB4R2 MAOB 886/4885SYK 2394/4885CCNC 3082/4885
US-20090062530-A1 Substituted arylalkanoic acid derivatives and use thereof CYSLTR1, CYSLTR2, LTB4R2 MAOB 886/4885SYK 2394/4885CCNC 3082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.